HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys.

Abstract
The opioid agonists morphine, etorphine, buprenorphine and U50,488 were examined alone and in combination with the insurmountable opioid antagonist clocinnamox (C-CAM) in squirrel monkeys responding under a schedule of shock titration. In this procedure, shock intensity increased every 15 sec from 0.01 to 2.0 mA in 30 increments. Five lever presses during any given 15-sec shock period produced a 15-sec timeout, after which shock resumed at the next lower intensity. When given alone, each of these agonists increased the median intensity at which the monkeys maintained shock [median shock level (MSL)]. At the highest dose examined alone, each agonist produced maximal increases in MSL and, except buprenorphine, decreased response rates. C-CAM dose-dependently antagonized the effects of morphine, etorphine and buprenorphine on MSL. In the presence of the higher C-CAM doses, etorphine, morphine and buprenorphine did not produce maximal effects on MSL. The effects of U50,488 were not systematically altered when tested in combination with the highest C-CAM dose. In general, C-CAM was more potent and the duration of antagonism was slightly longer against buprenorphine than against morphine and etorphine. Quantitative analysis of these data according to an extended model of yielded the following apparent affinity and efficacy estimates, respectively: etorphine (0. 085 mg/kg, 117); morphine (49 mg/kg, 24) and buprenorphine (0.62 mg/kg, 7.1). Determination of the individual q values over time indicated that the receptor population recovers more quickly after C-CAM antagonism of etorphine than from C-CAM antagonism of either morphine or buprenorphine. These data suggest that C-CAM functions as a long-lasting antagonist of mu opioid agonist actions in a shock titration procedure and yields estimates of relative intrinsic efficacy with the rank order of etorphine > morphine > buprenorphine.
AuthorsR C Pitts, R M Allen, E A Walker, L A Dykstra
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 285 Issue 3 Pg. 1197-206 (Jun 1998) ISSN: 0022-3565 [Print] United States
PMID9618423 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Analgesics, Non-Narcotic
  • Analgesics, Opioid
  • Anesthetics, Combined
  • Antigens, CD
  • CD66 antigens
  • Cell Adhesion Molecules
  • Cinnamates
  • Glycoproteins
  • Morphine Derivatives
  • Narcotic Antagonists
  • clocinnamox
  • Buprenorphine
  • Etorphine
  • 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
  • Morphine
Topics
  • 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer (pharmacology)
  • Analgesics, Non-Narcotic (pharmacology)
  • Analgesics, Opioid (pharmacology)
  • Anesthetics, Combined (pharmacology)
  • Animals
  • Antigens, CD
  • Buprenorphine (pharmacology)
  • Cell Adhesion Molecules
  • Cinnamates (pharmacology)
  • Etorphine (pharmacology)
  • Glycoproteins (pharmacology)
  • Male
  • Morphine (pharmacology)
  • Morphine Derivatives (pharmacology)
  • Narcotic Antagonists (pharmacology)
  • Pain Measurement (drug effects)
  • Saimiri

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: